This report helps to analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Gene Therapy for Ovarian Cancer Market.
About Gene Therapy
Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor, and stromal ovarian tumor are some of the less common types.
It is the seventh most common cancer in women globally and 18th most common cancer overall. The ovarian cancer immunotherapies market has already got some commercially successful chemotherapy products.
However, chemotherapy often involves a combination of two or more drugs, given intravenously every 3-4 weeks, and mostly associated with long-lasting side/adverse effects. Various studies have shown that chemotherapy can damage the blood-producing cells of the bone marrow, resulting in blood-related complications.
Gene Therapy is emerging as one of the most exciting approaches for the treatment of ovarian cancer. Replacement gene therapy, which replaces faulty genes with normal ones in the body, is particularly promising and currently gaining attention.
It has potential to cure ovarian cancer and can be used as a promising option for long-lasting treatment.
Covered in this report
The report covers the present scenario and the growth prospects of the gene therapy for ovarian cancer for 2018-2022. To calculate the market size, the report considers the revenue generated from the gene therapy.
Gene Therapy for Ovarian Cancer- A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years.
The report also includes a discussion of the key vendors operating in this market.
- Takara Bio
- Lokon Pharma
- SiBiono GeneTech
Browse Full Report with TOC: orbisresearch.com/reports/index/ge…-analysis-report
- The adoption of replacement gene therapy
- For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Takara Bio, VBL, Therapeutics, Targovax, CELSION, Lokon Pharma, SiBiono GeneTech, and Advantagene
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: GENE THERAPY FOR OVARIAN CANCER: AN INSIGHT
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
Mid-stage molecules (Phase II and I/II), 2017
Early-stage molecules (Phase I), 2017
Inactive molecules, 2017
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 10: THERAPEUTIC ASSESSMENT (BY TARGET)
PART 11: KEY COMPANIES
Active companies: Category and parameters
List of abbreviations
Category: Market Research Publishers and RetailersCompany about: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have a vast database of reports from the leading publishers and authors across the gl obe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their need, and we produce the perfect requi ...